AnHeart Therapeutics Announces Exclusive License Agreement With Nippon Kayaku for Taletrectinib in Japan
TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) and Nippon Kayaku Co., Ltd. (TOKYO: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin (generic name, development code: SP-02) in Japan (hereinafter “this agreement”).
Eiger BioPharmaceuticals, Inc. today announced a license agreement with Nippon Kayaku Co., Ltd., Tokyo, Japan, to develop Bestatin™ (ubenimex) for Pulmonary Arterial Hypertension as well as other inflammatory diseases involving leukotriene B4 (LTB4). Bestatin is a well-characterized, oral, small molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the enzyme responsible for converting LTA4 to LTB4, a naturally occurring inflammatory mediator. Bestatin has been marketed in Japan by Nippon Kayaku for over 25 years for a different indication.